Presseportal.ch - Joint source of Boehringer Ingelheim GmbH and Pfizer Inchttps://www.presseportal.ch/de/nr/100017983?langid=2Presseportal.ch: Joint source of Boehringer Ingelheim GmbH and Pfizer Inc (Newsroom)de-denews aktuell schweiz AGhttps://www.presseportal.ch/images/logos/logo-ch-250.jpgPresseportal.ch - Joint source of Boehringer Ingelheim GmbH and Pfizer Inchttps://www.presseportal.ch/de/nr/100017983?langid=2info@newsaktuell.ch (presseportal.ch)Sun, 10 May 2026 16:14:32 +0200Fri, 28 Aug 2009 01:06:24 +0200Joint source of Boehringer Ingelheim GmbH and Pfizer Inc6Data From Largest GOLD Stage II Patient Population Treated With Tiotropium Highlight the Benefits of Earlier Treatment of COPDJoint source of Boehringer Ingelheim GmbH and Pfizer Inc: Ingelheim, Germany (ots/PRNewswire) - - New UPLIFT(R) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease - Not for US Media A new analysis of the landmark ...https://www.presseportal.ch/de/pm/100017983/100588869?langid=2Fri, 28 Aug 2009 01:06:24 +0200https://www.presseportal.ch/de/pm/100017983/100588869?langid=2 Joint source of Boehringer Ingelheim GmbH and Pfizer Inc [Newsroom]
Ingelheim, Germany (ots/PRNewswire) - - New UPLIFT(R) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease - Not for US Media A new analysis of the landmark ... Lesen Sie hier weiter...

]]>Wirtschaftinfo@newsaktuell.ch (presseportal.ch)Joint source of Boehringer Ingelheim GmbH and Pfizer Inc